Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-05-30
2009-12-08
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S255060, C544S405000, C544S406000, C544S407000, C544S315000, C546S268100
Reexamination Certificate
active
07629346
ABSTRACT:
The present invention relates to compounds of the formula I:wherein R1to R8are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with the modulation of CB1 receptors, such as obesity.
REFERENCES:
patent: 3940418 (1976-02-01), Hamilton
patent: 5462960 (1995-10-01), Barth et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5624941 (1997-04-01), Barth et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6355631 (2002-03-01), Achard et al.
patent: 6432984 (2002-08-01), Barth et al.
patent: 6479479 (2002-11-01), Achard et al.
patent: 6509367 (2003-01-01), Martin et al.
patent: 6566356 (2003-05-01), Achard et al.
patent: 6645985 (2003-11-01), Barth et al.
patent: 6734176 (2004-05-01), Achard et al.
patent: 6872717 (2005-03-01), Achard et al.
patent: 6893659 (2005-05-01), Abramovici et al.
patent: 6906080 (2005-06-01), Barth et al.
patent: 7037944 (2006-05-01), Piot-Grosjean et al.
patent: 7132414 (2006-11-01), Achard et al.
patent: 7148258 (2006-12-01), Piot-Grosjean et al.
patent: 7229999 (2007-06-01), Hebeisen et al.
patent: 2001/0027193 (2001-10-01), Achard et al.
patent: 2002/0019383 (2002-02-01), Achard et al.
patent: 2002/0091114 (2002-07-01), Piot-Grosjean et al.
patent: 2002/0188007 (2002-12-01), Barth et al.
patent: 2003/0003145 (2003-01-01), Abramovici et al.
patent: 2003/0055033 (2003-03-01), Achard et al.
patent: 2003/0119810 (2003-06-01), Achard et al.
patent: 2004/0039024 (2004-02-01), Barth et al.
patent: 2004/0157823 (2004-08-01), Achard et al.
patent: 2004/0192667 (2004-09-01), Makriyannis et al.
patent: 2004/0259887 (2004-12-01), Dow
patent: 2005/0032773 (2005-02-01), Piot-Grosjean et al.
patent: 2005/0032774 (2005-02-01), Piot-Grosjean et al.
patent: 2005/0130953 (2005-06-01), Achard et al.
patent: 2005/0192332 (2005-09-01), Barth et al.
patent: 2006/0189664 (2006-08-01), Barth et al.
patent: 2006/0258709 (2006-11-01), Piot-Grosjean et al.
patent: 2008/0070931 (2008-03-01), Hebeisen et al.
patent: 2008/0085905 (2008-04-01), Dietz et al.
patent: 576357 (1993-12-01), None
patent: 656354 (1995-06-01), None
patent: 658546 (1995-06-01), None
patent: 2856684 (2004-12-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 97/19063 (1997-05-01), None
patent: WO 98/31227 (1998-07-01), None
patent: WO 98/41519 (1998-09-01), None
patent: WO 98/43635 (1998-10-01), None
patent: WO 98/43636 (1998-10-01), None
patent: WO 00/15609 (2000-03-01), None
patent: WO 00/46209 (2000-08-01), None
patent: WO 01/32663 (2001-05-01), None
patent: WO 01/64632 (2001-09-01), None
patent: WO 01/64633 (2001-09-01), None
patent: WO 01/64634 (2001-09-01), None
patent: WO 01/70700 (2001-09-01), None
patent: WO 02/28346 (2002-04-01), None
patent: WO 03/051850 (2003-06-01), None
patent: WO 03/051851 (2003-06-01), None
patent: WO 03/084930 (2003-10-01), None
patent: WO 2004/0099157 (2004-11-01), None
patent: WO 2004/110453 (2004-12-01), None
patent: WO 2004/111033 (2004-12-01), None
patent: WO 2004/111033 (2004-12-01), None
patent: WO 2004/111034 (2004-12-01), None
patent: WO 2004/111039 (2004-12-01), None
patent: WO 2004111038 (2004-12-01), None
patent: WO 2006/106054 (2006-10-01), None
patent: WO 2007/011760 (2007-01-01), None
Pacheco et al., J. Pharmacol. Exp. Ther., 257(1), pp. 170-183 (1991).
Casiano et al., NIDA Res. Monogr., 105, pp. 295-296 (1991).
Hosohata et al., Life Sci., 61, pp. 115-118 (1997).
Pertwee et al., Life Sci., 56(23-24), pp. 1949-1955 (1995).
Felder et al., J. Pharmacol. Exp. Ther., 284(1), pp. 291-297 (1998).
Kanyonyo et al., Bioorg. Med. Chem. Lett. 9(15), pp. 2233-2236 (1999).
Ooms et al., J. Med. Chem., 45(9), pp. 1748-1756 (2002).
Barth et al., “Cannabinoid Antagonists; From Research Tools to Potential New Drugs”, Abstracts of Papers, 222ndACS National Meeting, Chicago, IL, USA, Aug. 26-30, 2001.
Database Beilstein, XP002457050 & Agric. Biol. Chem., vol. 48, No. 4, pp. 1009-1016 (1984).
Hebeisen Paul
Iding Hans
Nettekoven Matthias Heinrich
Obst Sander Ulrike
Roever Stephan
Hoffmann-La Roche Inc.
Johnston George W.
McDowell Brian
Remy Brian C.
Tramaloni Dennis P.
LandOfFree
Pyrazinecarboxamide derivatives as CB1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazinecarboxamide derivatives as CB1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazinecarboxamide derivatives as CB1 antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4107243